Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
ONCT-534
i
Other names:
ONCT-534, GTx-534, SARD compounds, UT-34
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
Oncternal Therap
Drug class:
Androgen receptor inhibitor, Androgen receptor degrader
Related drugs:
‹
enzalutamide capsule (78)
darolutamide (14)
bicalutamide (13)
flutamide (4)
EPI-7170 (1)
SID 3712502 (1)
rezvilutamide (0)
MVI-118 (0)
enzalutamide tablet (0)
ARV-110 (6)
AC0176 (1)
EPI-8207 (0)
HRS-5041 (0)
ARV-766 (0)
enzalutamide capsule (78)
darolutamide (14)
bicalutamide (13)
flutamide (4)
EPI-7170 (1)
SID 3712502 (1)
rezvilutamide (0)
MVI-118 (0)
enzalutamide tablet (0)
ARV-110 (6)
AC0176 (1)
EPI-8207 (0)
HRS-5041 (0)
ARV-766 (0)
›
Associations
(1)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
ONCT-534
Sensitive: B - Late Trials
ONCT-534
Sensitive
:
B
ONCT-534
Sensitive: B - Late Trials
ONCT-534
Sensitive
:
B
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login